[Challenges in Drug Development Targeting Anti-atherosclerotic Proteins]

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Molecular Biology

Background:

• Atherosclerosis is a major global cause of death, with increasing prevalence in Japan.
• High-density lipoprotein (HDL) is known for its protective role against atherosclerosis, attributed to reverse cholesterol transport and anti-inflammatory properties.
• Current HDL-modulating therapies for cardiovascular risk reduction are unavailable.

Purpose of the Study:

• To investigate the function of HDL-related proteins, including those regulating HDL production (ATP-binding cassette transporters) and HDL-binding proteins.
• To explore the potential of apolipoprotein A-I (apoA-I) binding protein (AIBP) in enhancing HDL function.
• To identify potential prognostic and therapeutic strategies for cardiovascular disease.

Main Methods:

• Focus on the function of HDL-related proteins.
• Investigate ATP-binding cassette transporters involved in HDL production.
• Analyze HDL-binding proteins and their role in HDL function.

Main Results:

• Apolipoprotein A-I (apoA-I) binding protein (AIBP) may enhance HDL function by promoting lipid release and reducing inflammation.
• Studies on HDL-related proteins provide insights into HDL's protective mechanisms.
• Research highlights the importance of HDL-binding proteins in cellular lipid regulation.

Conclusions:

• Understanding HDL-related proteins is crucial for developing novel cardiovascular disease therapies.
• Targeting HDL function presents a promising avenue for reducing atherosclerosis burden.
• Further research into HDL-binding proteins and their regulatory roles could yield significant clinical benefits.